HistoCyte at NordiQC
At the NordiQC meeting in Aalborg, HistoCyte laboratories Ltd were invited to present as one of the sponsoring companies. Dr Ian Milton talked about one of our leading works in R&D: ALK Analyte ControlDR.
While HistoCyte Laboratories currently have two products for ALK in Lung and Lymphoma, we know from experiences with our customers and from working closely with various external quality assurance (EQA) schemes that some still struggle with their assay optimisation and appropriate sensitivity for the specific ALK translocation, or more specifically the resulting fusion protein. In this presentation, Dr Milton discussed the combination of cells containing EML4-ALK (associated with non-small cell lung carcinoma), NPM-ALK (associated with anaplastic large cell lymphoma), Wt ALK and a negative control. This combination clearly demonstrates the appropriate sensitivity of the ALK assays.
This product is expected to be launched in early 2018. For any enquiries, please contact info@histocyte.